2026年9月3日，EngiTissue Design株式会社参加了在新加坡Suntec Singapore Convention & Exhibition Centre举办的ISCT Asia 2026 Regional Meeting（International Society for Cell & Gene Therapy，国际细胞与基因治疗学会 亚洲区域会议）。
在本次会议上，本公司李俊君的摘要被选为口头报告（Oral Presentation），并在Oral Session 2进行了发表。
报告题目：A dual excitation-contraction platform for functional evaluation and drug safety assessment of human iPSC-derived cardiac tissues
在本次报告中，我们利用人类iPSC（诱导多能干细胞）来源的心肌组织，介绍了一种用于评价其功能并应用于药物安全性评价的平台。同时还进行了海报展示，与参会的研究人员和专家进行了热烈交流。
本公司持续开发利用iPSC来源组织的功能评价与药物安全性评价技术。今后也将通过此类国际学术交流，发布研究成果并构建全球网络。
相关论文
- Clinical and experimental insights into hydroxychloroquine-associated electrical abnormalities and cardiomyopathy. https://doi.org/10.1093/ehjcvp/pvag063
- Enabling dual excitation-contraction recording and disease modeling via hydrogel-free heart tissue. https://doi.org/10.1016/j.xcrp.2025.103068
- Phenotypic recapitulation and correction of desmoglein-2-deficient cardiomyopathy using human-induced pluripotent stem cell-derived cardiomyocytes. https://doi.org/10.1093/hmg/ddab127
- Human pluripotent stem cell-derived cardiac tissue-like constructs for repairing the infarcted myocardium. https://doi.org/10.1016/j.stemcr.2017.09.007
- Human induced pluripotent stem cell-derived closed-loop cardiac tissue for drug assessment. https://doi.org/10.1016/j.isci.2024.108992
- Circulating re-entrant waves promote maturation of hiPSC-derived cardiomyocytes in self-organized tissue ring. https://doi.org/10.1038/s42003-020-0853-0